<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04032847</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-NS-001</org_study_id>
    <nct_id>NCT04032847</nct_id>
  </id_info>
  <brief_title>ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC</brief_title>
  <official_title>An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achilles Therapeutics UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Achilles Therapeutics UK Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the&#xD;
      safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT)&#xD;
      administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterise the&#xD;
      safety and clinical activity of autologous clonal neoantigen reactive T cells (cNeT)&#xD;
      administered intravenously in adults with advanced non-small cell lung cancer (NSCLC).&#xD;
&#xD;
      Patients will initially enter the study for procurement of tumour materials required to&#xD;
      manufacture ATL001.&#xD;
&#xD;
      Following manufacture of ATL001, the product will be given back to eligible patients&#xD;
      following lymphodepletion. Patients will be followed up for a period of 24 months post ATL001&#xD;
      infusion in the study. Patients will then be requested to enter a separate long term follow&#xD;
      up protocol for a further 5 years (total 84 months)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Treatment Emergent Adverse Events (TEAEs) to evaluate Safety and Tolerability</measure>
    <time_frame>84 months</time_frame>
    <description>Evaluate TEAEs and serious AEs, by incidence, severity and relationship to ATL001</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Assessment for Change from Baseline in Tumour Size</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the clinical activity of ATL001 in patients with advanced NSCLC using change from baseline in tumour size at week 6 , week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease Assessment for Objective Response Rate (ORR)</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the endpoint of ORR as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST).</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Assessment for Time to Response (TTR) from ATL001 infusion</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the endpoint of TTR by the investigator and ICR, per RECIST v1.1 and im-RECIST</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Assessment for Duration of Response (DoR). The DoR is defined as the time from the date of first documented response until the date of documented disease progression or death</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the endpoint of DOR by the investigator and ICR, per RECIST v1.1 and im-RECIST</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Assessment for Disease Control Rate (DCR)</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the endpoints of DCR as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Assessment for Progression-Free Survival (PFS)</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate the efficacy endpoints of PFS as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months</time_frame>
    <description>Evaluate OS by the investigator</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following lymphodepletion, infusion of cell therapy product ATL001.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATL001</intervention_name>
    <description>ATL001 infusion</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Checkpoint inhibitor</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient must be at least 18 years old.&#xD;
&#xD;
          2. Patient must have given written informed consent.&#xD;
&#xD;
          3. Confirmed diagnosis of non-small cell lung cancer that is considered to be smoking&#xD;
             related.&#xD;
&#xD;
          4. ECOG Performance status 0-1&#xD;
&#xD;
          5. Anticipated life expectancy â‰¥ 6 months at the time of tissue procurement.&#xD;
&#xD;
          6. Measurable disease according to RECIST 1.1 criteria.&#xD;
&#xD;
          7. Adequate organ function per the laboratory parameters defined in the protocol.&#xD;
&#xD;
          8. Patient is considered medically fit to undergo procurement of starting material and&#xD;
             ATL001 administration procedures.&#xD;
&#xD;
          9. Patient is considered, in the opinion of the investigator, capable of adhering to the&#xD;
             protocol.&#xD;
&#xD;
         10. Female patients who are of childbearing potential must agree to use a highly effective&#xD;
             method of contraception during the study for at least 12 months after the ATL001&#xD;
             infusion, and for at least 4 months after the last dose of pembrolizumab.&#xD;
             Non-sterilised male participants who intend to be sexually active with a female&#xD;
             partner of childbearing potential must use an acceptable method of contraception from&#xD;
             the time of screening, throughout the duration of the study and for at least 6 months&#xD;
             after the ATL001 infusion.&#xD;
&#xD;
         11. Patients must have received a PD-1/ PD-L1 inhibitor prior to treatment with ATL001&#xD;
             (unless contraindicated).&#xD;
&#xD;
        Additional Inclusion Criteria will apply as per the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with evidence of CNS metastases.&#xD;
&#xD;
          2. Patients with active infectious disease.&#xD;
&#xD;
          3. Patients who are non-smokers.&#xD;
&#xD;
          4. Patients requiring immunosuppressive treatments.&#xD;
&#xD;
          5. Patients requiring regular treatment with systemic steroids.&#xD;
&#xD;
          6. Patients with superior vena cava syndrome.&#xD;
&#xD;
          7. Patients with clinically significant, progressive, and/or uncontrolled renal, hepatic,&#xD;
             haematological, endocrine, pulmonary, cardiac, gastroenterological or neurological&#xD;
             disease.&#xD;
&#xD;
          8. Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          9. Patients who have undergone major surgery in the previous 3 weeks.&#xD;
&#xD;
         10. Patients with an active concurrent cancer or a history of cancer within the past 3&#xD;
             years (except for in situ carcinomas or non-melanomatous skin cancers).&#xD;
&#xD;
         11. Patients with a history of organ transplantation.&#xD;
&#xD;
         12. Patients who have received any investigational cell or gene therapies.&#xD;
&#xD;
         13. Patients with contraindications for protocol specified agents.&#xD;
&#xD;
         14. Patients with a history of immune mediated central nervous system toxicity with causal&#xD;
             or suspected causal link to immunotherapy.&#xD;
&#xD;
         15. Patients with a history of â‰¥ Grade 2 diarrhoea/colitis caused by previous&#xD;
             immunotherapy within 6 months of screening. Patients that have been asymptomatic for&#xD;
             at least 6 months or have had a normal colonoscopy post-immunotherapy (with uninflamed&#xD;
             mucosa by visual assessment) are not excluded.&#xD;
&#xD;
        Additional Exclusion Criteria will apply as per the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Achilles Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior VP Clinical Operations Achilles Therapeutics, PhD</last_name>
    <phone>+44 (0)208 154 4600</phone>
    <email>info@achillestx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Hurwitz, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Unit</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Creelan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Schoenfeld, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Clarke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SÃ©bastien Couraud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Besse, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Carl Gustav Carus an der TU Dresden Anstalt des Ã¶ffentlichen Rechts des Freistaates Sachsen</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Wermke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Schuler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enriqueta Felip, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario FundaciÃ³n JimÃ©nez DÃ­az</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno Garcia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Middleton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Doherty, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The LeedsTeaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Collinson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Forster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE19RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Spicer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona Thistlethwaite, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alastair Greystoke, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Cave, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2019</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

